ReviewMaterials today. Bio2025
Advances in nanomaterials for enhancing cGAS-STING pathway mediated anti-tumor treatment.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gene therapy for liver diseases: methods, challenges and opportunities.Journal of nanobiotechnology · 2026Review
- Dual-Function Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization.Drug development research · 2026Review
- Leveraging the crosstalk between cGAS-STING and pyroptosis by nanomedicine to enhance antitumor immunity.Journal of nanobiotechnology · 2026Review
- A NIR-Ⅱ-Immunostimulatory nanoplatform rewires immunometabolism to unleash STING-driven antitumor immunity.Journal of nanobiotechnology · 2026Article
- Research progress on the spatiotemporal dynamics of therapy-induced senescence in remodeling the tumor microenvironment.Frontiers in immunology · 2026Review
- Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy.International journal of nanomedicine · 2026Review
- The cGAS‒STING pathway in colorectal cancer: bridging innate immunity and therapeutic strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cGAS-STING pathway is a crucial component of innate immunity, playing a dual role in tumor biology by promoting pro-inflammatory responses and anti-tumor immunity. Nanomaterials have emerged as transformative tools to enhance the activation and therapeutic efficacy of this pathway in cancer immunotherapy. This review targets recent advancements in nanomaterials of enhancing cGAS-STING-mediated anti-tumor immune responses. These nanomaterials leverage their unique physical and chemical properties for targeted delivery, controlled release, and biodegradability, significantly improving the anti-tumor effects through synergistic activation of the cGAS-STING pathway. This review underscores the potential of nanomaterial-based cGAS-STING therapeutics for cancer treatment and identifies key research priorities to address existing limitations and propel the field forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.